Fujifilm Invests $1.6 Billion toward Expansion of Cell Culture Manufacturing Services

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines, and viral vectors, is investing $1.6 billion to enhance and expand its cell culture manufacturing services. This investment will boost Fujifilm’s sites in Hillerød, Denmark, and College Station, TX.

As part of this investment, the CDMO is further growing its capacity to support large-scale current good manufacturing practice (cGMP) fed batch production by adding 8 x 20,000L bioreactors and two downstream processing streams in its Hillerød, Denmark facility. According to the company, the additional production capacity will make the Hillerød facility the largest end-to-end CDMO in Europe, offering a total of 20 x 20,000L bioreactors for drug substance production, alongside drug product and finished goods services.

In regard to the College Station site, Fujifilm will use its branded SymphonX production equipment, enabling current good manufacturing practice (cGMP) MaruX continuous processing at the single-use cell culture manufacturing site.

“Fujifilm is further expanding its bio CDMO business with the growth strategy of both capital investment and technological innovation to fulfill rapidly growing demand for high volume production of biopharmaceuticals,” comments Teiichi Goto, president, CEO, and representative director, FUJIFILM Corporation. “ … Fujifilm will, through creation of new value from innovation, contribute to the stable supply of high-quality biopharmaceuticals, and to promoting a healthy society and further growth of healthcare industry.”